<DOC>
	<DOCNO>NCT02847650</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability PF-06649751 Parkinson 's disease patient early stage disease .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability PF-06649751 Parkinson 's Disease Patients Early Stage Disease</brief_title>
	<detailed_description>The B7601011 study randomize , double-blind , placebo-controlled parallel group design . Approximately 88 subject randomize 2 treatment group . Each subject participate study approximately 23 week include 30 day screen period , 15 week double blind treatment period , approximately 28 day follow-up period .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Females nonchildbearing potential and/or male subject Clinical diagnosis Parkinson 's disease . Parkinson 's Disease Hoehn &amp; Yahr Stage IIII inclusive Treatment na√Øve history prior incidental treatment dopaminergic agent 28 day Able refrain Parkinson 's disease medication permit protocol . History presence atypical Parkinsonian syndrome . Severe acute chronic medical psychiatric condition cognitive impairment laboratory abnormality . Any condition possibly affect drug absorption . Participation study involve investigational drug ( ) , treatment investigational drug within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Early Parkinson Disease</keyword>
	<keyword>Phase 2</keyword>
</DOC>